A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.
GSK Clinical Trials, MD
Study Director
GlaxoSmithKline
United States: Food and Drug Administration
767905/008
NCT00101998
October 2003
Name | Location |
---|---|
GSK Investigational Site | Phoenix, Arizona 85013 - 4496 |
GSK Investigational Site | Little Rock, Arkansas 72205 |
GSK Investigational Site | Bakersfield, California 93309 |
GSK Investigational Site | Gainesville, Florida 32610 |
GSK Investigational Site | Springfield, Massachusetts 01107 |
GSK Investigational Site | Duluth, Minnesota 55805 |
GSK Investigational Site | St. Louis, Missouri 63141 |
GSK Investigational Site | Albuquerque, New Mexico 87109 |
GSK Investigational Site | Raleigh, North Carolina 27609 |
GSK Investigational Site | Akron, Ohio 44304 |
GSK Investigational Site | Fort Worth, Texas 76104 |
GSK Investigational Site | Green Bay, Wisconsin 54301 |
GSK Investigational Site | Savannah, Georgia 31405 |
GSK Investigational Site | Park Ridge, Illinois 60068 |
GSK Investigational Site | Bettendorf, Iowa 52722 |
GSK Investigational Site | Baltimore, Maryland 21201 |
GSK Investigational Site | Royal Oak, Michigan 48073 |
GSK Investigational Site | Fargo, North Dakota 58103 |
GSK Investigational Site | Germantown, Tennessee 38138 |
GSK Investigational Site | Salem, Virginia 24153 |
GSK Investigational Site | New York, New York 10021 |
GSK Investigational Site | Aurora, Colorado 80012 |
GSK Investigational Site | Washington, District of Columbia 20307-5001 |
GSK Investigational Site | Kansas City, Kansas 66160 |
GSK Investigational Site | Henderson, Nevada 89014 |
GSK Investigational Site | Oregon City, Oregon 97045 |
GSK Investigational Site | Seattle, Washington 98133 |